Collinge BJ, Hilton LK, Wong JCH, Alduaij W, Ben-Neriah S, Slack GW, Farinha P, Boyle M, Meissner B, Cook JR, Ott G, Rosenwald A, Campo E, Amador C, Greiner TC, Raess PW, Song JY, Inghirami GG, Ondrejka SL, Jaffe ES, Weisenburger DD, Chan WC, Holte H, Beiske K, Fu K et al. (2025)
High-grade B-cell lymphoma, not otherwise specified: an LLMPP study
Blood Adv (in press)
DOI 10.1182/bloodadvances.2025016651, PubMed 40674706

Skourti E, Seip K, Mensali N, Jabeen S, Juell S, Øynebråten I, Pettersen S, Engebraaten O, Corthay A, Inderberg EM, Dolznig H, Mælandsmo GM, Egeland EV, Prasmickaite L (2025)
Chemoresistant tumor cell secretome potentiates immune suppression in triple negative breast cancer
Breast Cancer Res, 27 (1), 131
DOI 10.1186/s13058-025-02082-x, PubMed 40660361

Sorbye H, Hjortland GO, Vestermark LW, Ladekarl M, Svensson J, Sundlöv A, Janson ET, Garresori H, Hofsli E, Kersten C, Elvebakken H, Pfeiffer P, Morken S, Assmus J, Lothe IMB, Tabaksblat E, Knigge U, Couvelard A, Perren A, Langer SW (2025)
Correction: Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study
Br J Cancer (in press)
DOI 10.1038/s41416-025-03095-1, PubMed 40659859